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Introduction
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• , e. f .u i c i i reported to be transient: after a few months lgb levels Hyposensitization therapy of allergic rhinitis has been usually decline to pre-therapy or slightly lower levels. It is shown to cau.se an increase in allergen specific IgE, early not clear whether the early increase is explained by higher production of IgE with already existing epitope-specificity. Correspnndcncc: Dr R. van IgE responses were monitored against whole allergen extracts. In this way. possible new specificities and changes in the relalive importance of single allergens remain undetected. Only in a tew cases was IgE against single allergens studied 13-5], By means of immunohlotting. induction of "new" IgE antibndics against minor allergens from birch and grass pollen was demonstrated [6.7|. To find out whether induction of IgE against major allergens or shifts in the relative importance of individual allergens occur, a group of sera of patients receiving grass pollen immunotherapy was studied. IgE antibodies were measured against four purified grass pollen allergens, Lol p 1, 2, 3, and 5, before and in the course of IT.
Materials and methods

Human subjects
All sera were obtained from patients {n -64} receiving grass pollen IT. Four different groups were included. The hrst group contained sera from 10 patients (KI-IO) involved in a double-blind study in Poland |8]. Serum samples were taken at the start of therapy {October/ November) and preseasonally (April) in the first year of therapy. The second group contained U) patients (SI-10) from ihe Netherlands who were followed during several years of IT. Serum samples were taken at four time-points in three consecutive years: January/February, May. July and October. In some cases an additional sample was analysed, taken in the sixth pollen season (July), following the start of therapy.
The third group contained sera from 30 patients (DI-30) from the Netherlands. .Serum samples were taken at the start of therapy and 11-15 months later (mean: 13 months). The final group of sera was from 14 patients (BI-I4) from the Netherlands. Serum samples were taken at the start of therapy, and at variable times afterwards (5 to 18 monihs; mean: 10 months).
Treatment was performed with Purethal'**'-grasses (HAL Allergen Laboratories. Haarlem, The Netherlands) for patients Kl-10, with Alutard Grassmix-.5 SQ 293 (ALK. Horsholm. Denmark) for patients Dl-30 and BI-14. and with Pharmacia Grassmix-4 (Pharmacia, Uppsala. Sweden) for patients SI-10.
Allergens
Grass {Lolium perenne) pollen was obtained from Diephuis Laboratories (Groningen. The Netherlands). Extraction was performed as described previously [9) . Purified Lol p I. Lo! p 2. and Lol p 3 were obtained from the National Institute of Allergy and infectious Diseases (Belhesda. Maryland. USA): NIH research reagents A611-901-IS.-i, A612-90I-185. and A612-90I-185 respectively. Purified Lol p 5 was obtained by monoclonal antibody (4B1) af hnity-purification as described elsewhere [9] . The source of recombinant Dae g 2 was a crude E. coli lysate containing a /3-galactosidase-Dac g 2 fusion protein |10,l 1]. Purified Lol p I. 2. 3 and 5 were coupled to CNBr-activated Sepharose (Pharmacia. Uppsala. Sweden) tor application in RAST tl(K)/ig allergen on 100 mg of Sepharose).
Radio aliergosorbent test {RAST)
RAST was performed as described previously 112]. Results were expressed in RAST units (RU). A standard curve was made by measuring the response obtained with a reference serum with known total IgE in a two-site assay with Sepharose-coupled sheep-antihuman IgE and '"''I-labelled anti-IgE. Results < 0.1 RU were regarded as negative.
Depletion for IgG
Depletion for IgG antibodies was performed by a 4 h incubation (end-over-end at room temperature) of 100//I serum with 100 mg Sepharose-coupled Protein G (Pharmacia) in a final volume of I ml (PBS/0.3% BSA/O.I% Tween 20). As a negative control Sepharose-coupled glycine was used, instead of Protein G-Sepharose. Total IgG and total IgE were tested in the unbound traction to monitor the specificity of the depletion. In all cases depletion was effective: <5% IgG was left in the supernatant. Total IgE did not significantly change by the procedure (< 10%).
Immunohlottin}Î mmunoblotting was performed with crude E. coli lysates (reconibinant Dae g 2) separated by SDS-PAGE, as described previously [ 111.
Statistical analysis
Pre-and post-immune serum IgE levels against Lol p 1. 2. 3 and 5 were compared by means of a Student's ^test (paired; two-tailed).
Results
IgE against Lol p I, 2. .? and 5
All pre-and post-immune sera in = M) were tested in a RAST for Lol p 1. 2, 3 and 5 (Eig. 1). The mean of the time interval between the two sample collections was 10 months. For Lol p 1, 2, and 3 a moderate increase of the mean IgE re.sponse was observed: 8.1 to 10 RU, 2.7 to 3.3 RU. and 3.0 to 3.3 RU, respectively. In contrast, for Lol p 5 a decrease respectively. In these patients the response to Lol p 5 did not change significantly (ratio I.I; 0.7<95% CI<L6). For serum samples taken > 6 months after the first immunization {ij = 40), the only significant change was a decrease for IgE to Lol p 5 (mean ratio: 0.50; 0.4<957r Ci<0.7).
For 53/64 patients a RAST for total Loliioii perenne pollen was performed. The mean response increased Irom 18.0 RU to 22.1 RU (mean ratio: 1.2; 1.1 <95% CI< 1.4). Within this group again a moderate, but non-significant, increase was observed for Lol p I. 2 and 3. whereas the response to Lol p 5 showed a significant decrease (mean ratio; 0.68; 0.52<95% CK0.89).
Depletion for IgG antibodies
For nine patients who demonstrated a decrease of specific IgE against Lol p 5. post-immune sera were depleted for IgG antibodies with Protein G-Sepharose. The depleted sera were te.sted in a RAST lor Lol p 5. After IgG removal. four out of nine sera (B6, SI, S2 and S6) showed a significant increase (25%, 29%, 58% and 27%, respectively) of IgE-binding to Lol p 5; for the other five this was not found (<5%).
Individual IgE antibody responses
The development of specific IgE among individual sera differed. In If) sera IgE against all four allergens decreased. Only two of these sera were taken within 6 months after the start of IT. Eor 14 sera. IgE against all four allergens increased. In this case serum samples were taken less than 6 months after initiation of the therapy, again with the exception of only two sera. Eor five patients no significant changes (< 10%) in IgE titres were found. One of these patients showed no binding to any ofthe purified allergens (RAST lor crude LoVnan perenne extract: 1.3 RU). Eor the remaining patients [n -29) the development of IgE titres against Lol p 1. 2. 3 and 5 was not consistent: an increase for one or more allergens was accompanied by a decrease for the remaining allergen(s) (Fig.2 ). For 10 patients intraserum ratios of IgE against two or more of the purified allergens changed by a factor o{ 5-400 (mean: 72).
Induction of !gE with new specificities
Five patients showed a conversion from negative f <0.1 RU) to positive (0.6 to 5.0 RU) in the RAST for one or more of the grass pollen allergens (shown for two patients in Fig.  2(a/b) ). This was observed twice for each of the four allergens. In some cases an existing but weak IgE respon.se increased up to ten-fold (shown for two patients in Fig, 2(c/d) ). Induction or increase of IgE was confirmed on itiimunoblot with recombinant Dae g 2 for several patients (Fig. 3) .
Persistence of newly induced IgE
Patients SI -10 were followed during several years of IT. At In the three following pollen seasons (1984-1986) specific IgE against Lol p 2 and 5 was delected, every year at a higher level (Fig. 4b ). Three years later (1989) an additional (weak) IgE response against Lol p 3 (0.3 RU) was found. By this time IgE levels against Lol p 2 and 5 had increased to 2.7 and 2.1 RU. respectively. This is > 10 times higher than at the start of the therapy. Another patient (S5) showed an increase of specific IgE against all four allergens, as judged © 1997 Blackwell Science Lid. Clinical and Experimental Allergy, 11. 6S-74 by RAST values found for serum samples taken in January/ February (Fig. 4c) . In contrast to this, a continuous decrease of specific IgE was observed for patient S3 (Fig, 4dJ .
Discussion
in this study, the mean IgE responses again.st total Lolium perenne pollen, of patients receiving grass pollen immunotherapy, were shown to increase in the first year of treatment (rt = 53). When analysis of IgE responses against four purified allergens was performed for these 53 patients, a pattern similar to the complete panel of 64 patients was found: a (non-significant) trend towards an increase for Lol p 1. 2 and 3. and a decrease for Lol p 5. This illustrates that measurement of specific IgE against a crude allergen source does not always give reliable information about the IgE response to its major allergens, in this case Lol p 5.
When serum samples, taken early after the start of therapy ree Dae g II (< 6 months) were analysed separately, an increase of IgE against Lol p 1.2 and 3 was observed. In the group of serutn samples taken at a later time point (> 6 months) no significant changes were found in these responses. This fits the generally accepted picture of a transient rise of IgE during the first months of IT [ 1 -31. For IgE responses to Lol p 5 the early rise was not found, and a decrease of the mean IgE titre was found at later time points. To investigate whether Lol p ."i-specific IgG was blocking the binding of IgE in the Lol p 5-RAST, nine sera were depleted for IgG. In four out of nine cases interference by IgG could (partially) explain the observed apparent decrease in Lol p 5-specific IgE. For the other sera this was not found, suggesting that IgE against Lol p 5 is really downregulated in these patients. Since the IgG depletion was only performed for a small selection of sera, we cannot determine whether the decrease in Lol p 5-specific IgB, observed for the whole group of patients {n -64), would still be significant after IgG removal. Furthermore, it is not clear why the immune response to Lol p 5 is different from the responses to the other three allergens. Perhaps Lol p 5 is less efficiently adsorbed in depot-materials, resulting in a higher exposure to this allergen, and thereby an earlier induction of (blocking) IgG or down regulation of TgE.
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It could be argued that the sera originated from too diversely treated patients to be statistically analysed as one group. When the four groups were analysed separately, similar trends were observed: igE responses to Lol p 1, 2 and 3 remained unchanged or slightly increased, whereas IgE against Lol p 5 decreased. The ratios of post/preimmune IgE responses against Lol p 5 for groups B. D. K and S were 0.8, 0.4, 0.7 and 0.9, respectively. Due to the low number of observations these figures were, however, not significant.
The changes ob.served in individual IgE patterns against the four purified grass pollen allergens illustrate that measurement of IgE against total pollen is not a very reliable parameter for monitoring specific IgE in time (e.g. during IT). It was for example found that the IgE level against Lolium perenne pollen decreased by a factor of 4, while IgE titres against several of its major allergenic components (Lol p 2, 3 and 5) simultaneously increased by at least a factor of 20 (Fig. 2b) . In several cases the opposite was observed: increase of IgE against total pollen, accompanied by a decrease of IgE against one or more of the purified allergens (Fig. 2a, c and d) .
Appearence of IgE with specificities not detected before IT is certainly not a desired effect of the treatment. This is especially true if the "new' IgE antibodies are directed to a major allergen like Lol p 1 or Lol p 5. In this study conversion from negative to positive was observed in about 8% (5/64) of the patients. This phenomenon was also observed in samples taken > 1 yr after the start of the therapy, indicating that it is not just a part of the transient increase of specific IgE early in the course of the treatment. The persistent character of newly induced IgE specificities was confirmed for two patients that were monitored during several years of therapy ( Fig. 4) .
Of course the observations in this study do not prove direct involvement of immunotherapy in the induction of new IgE antibodies. They could also have appeared 'spontaneously' by natural exposition. Whether these IgE antibodies have ciinicai relevance is also not clear. Investigating the development of specific IgE responses towards individual allergens in a placebo-controlled trial would be the best way to answer these questions. The main implication from this study is that measurement of IgE against crude allergen extracts can mask serologically important changes in specific TgE titres, not only in the sera of patients undergoing immunotherapy.
